ClinicalTrials.gg
RecruitingNCT07145489Updated Feb 4, 2026

Infrared Photobiomodulation in Humans With Epilepsy

An interventional study of photobiomodulation in Drug Resistant Epilepsy, sponsored by Beth Israel Deaconess Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Planned enrollment
48th of 67
13 · median 27
Started
2025
with 7 others
No phase
38 of 78
22 open now
Primary completion
2026-09
later than 4 of 33 live
Registered
67th of 78
by date

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 48th largest by planned enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 38 with no phase, reaches primary completion later than 4 of the 33 other live ones, and was the 67th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

Read the detailed description

Epilepsy affects 12 out of every 1000 people in the United States (1.2%). Of those, roughly 40% have drug-resistant epilepsy, meaning seizures do not stop despite good doses given with two different anti-seizure medications. Patients in this situation have several options (1) try additional medications (2) consider surgery to remove the part of the brain causing seizures, if possible (3) consider neuromodulation devices that change the brain activity using electricity in the brain (also a surgery) (4) try special diets such as the ketogenic diet which changes the fuel used by the brain by only eating certain foods. Despite these options, a large number of patients continue to have seizures. There is a great need for new treatments for drug resistant epilepsy.

The main purpose of this study is to determine if a new treatment is safe and well tolerated. Everyone in this study will receive the Red Light Therapy Hat which is investigational and is not approved by the FDA. The investigators do not know all the ways that this study treatment may affect people. This study is intended to hopefully help the participants, and the investigators hope the information from this study will help us develop a better treatment for drug resistant epilepsy in the future.

This particular investigational technology has been approved by the FDA for use in other diseases or conditions, but the investigators do not yet know if it is useful or safe as a treatment for drug resistant epilepsy.

03

Conditions studied

  • Drug Resistant Epilepsy

Keywords

  • epilepsy
  • photobiomodulation
  • seizure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Drug resistant epilepsy
  • Age 18 or older
  • Average seizure rate of at least 2 seizures per month
  • Accurate seizure diary with at least 3 months recorded

Exclusion criteria

Exclusion Criteria:

  • Implanted intracranial neurostimulation device (DBS or RNS)
  • Intracranial shunt
  • Skin photosensitivity
  • Cancer on scalp
  • Taking any medication that can cause photosensitivity
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    photobiomodulation

    participants will use photobiomodulation daily for 6 months

    Device: photobiomodulation

Interventions

  • Devicephotobiomodulation

    a hat with infrared lights will be worn for 30 minutes daily for 6 months

06

What researchers measure

Primary outcomes

  1. seizure rate reduction

    fraction of seizures reduced by therapy assessed by individual baseline rate

    Time frame: 6 months

  2. tolerability of daily photobiomodulation

    Do participants find it reasonable to use the therapy daily or do they request exiting from the study? Do participants report significant side effects as reported by weekly check-ins that make the therapy uncomfortable or intolerable?

    Time frame: 6 months

Secondary outcomes

  1. seizure duration

    fraction of seizure duration reduction assessed by baseline seizure durations

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data about seizure rates, seizure durations and side effects

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: 1 year after the completion of enrollment, and for at least 4 years thereafter

Access criteria: It will be made publicly accessible to anyone via public repository and via journal publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 10 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 28, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Sep 25, 2026
CompletionEst.
Sep 25, 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145489
Responsible party
Daniel Goldenholz (Assistant Professor, Beth Israel Deaconess Medical Center) — Principal investigator
First posted
Aug 28, 2025
Start date
Nov 25, 2025
Primary completion
Sep 25, 2026 (estimated)
Completion
Sep 25, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Daniel Goldenholz, MD, PhD
Contact
daniel.goldenholz@bidmc.harvard.edu
617-632-8930
Daniel Goldenholz, MD PhD
Contact
daniel.goldenholz@bidmc.harvard.edu
617-632-8930
Daniel Goldenholz, MD PhD
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion